Form 4: BioLife Solutions CSO Acquires Shares, Tax Withholding

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, reported the acquisition of restricted stock awards and a related tax withholding transaction.

Summary

• Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported transactions involving common stock on February 24, 2026.
• Acquired 20,096 shares of restricted stock as part of 2026 compensation, which will vest 25% on the first anniversary of the grant date and thereafter quarterly in 12 equal installments.
• Acquired an additional 39,605 shares of restricted stock, which vested based on the registrant's total shareholder return during January 1, 2024, through December 31, 2025, compared to a peer group.
• Disposed of 15,585 shares at a price of $22.65 per share to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
• Following these transactions, Mathew beneficially owns 393,466 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive, routine filing reflecting successful performance-based vesting and continued executive alignment through new restricted stock grants, indicating confidence in future performance.

Positives

• The grant of 20,096 restricted shares as part of 2026 compensation indicates continued executive incentive and alignment with future company performance.
• The vesting of 39,605 restricted shares based on the company's total shareholder return compared to peers suggests positive company performance over the January 1, 2024, to December 31, 2025, period.

Negatives

• The disposition of 15,585 shares to cover tax obligations, while a standard practice, reduces the direct share ownership of the executive.

Future Outlook

The vesting schedule for the 2026 compensation restricted stock award indicates future share ownership for the EVP & Chief Scientific Officer, aligning incentives with long-term company performance.

Management Comments

• The restricted stock grants are part of the BioLife Solutions 2023 Omnibus Performance Incentive Plan, designed to incentivize executives.
• Performance-based vesting for a portion of the restricted stock is tied to the registrant's total shareholder return compared to a peer group, reflecting a focus on relative performance.

Industry Context

StockSavvy.ai notes that performance-based restricted stock awards, particularly those tied to relative total shareholder return, are a common practice in the biotechnology and life sciences industry to align executive incentives with shareholder value creation and competitive performance.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) with multi-year vesting schedules is a standard practice in executive compensation across the S&P 500, including biotech firms like Thermo Fisher Scientific and Danaher Corporation, to promote long-term retention and performance alignment.
• Tying a portion of equity awards to relative total shareholder return (TSR) against a peer group, as seen here, is a sophisticated compensation design often employed by companies aiming for top-tier performance, similar to practices at companies such as Amgen or Gilead Sciences.
• The tax withholding mechanism for vested equity is a universal practice for publicly traded companies, ensuring compliance with tax regulations upon the realization of income from equity awards.

Stakeholder Impact

• Shareholders: The performance-based vesting of restricted stock suggests positive past performance relative to peers, potentially benefiting shareholders. New grants align executive incentives with future shareholder value.
• Employees: The compensation structure for executives can set a precedent or reflect the overall compensation philosophy within the company.

Next Steps

• The 20,096 restricted shares granted on February 24, 2026, will begin vesting 25% on the first anniversary of the grant date, with subsequent quarterly installments.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including restricted stock grants and tax-related share dispositions. While the performance-based vesting is a positive indicator of past relative performance, these transactions are standard and do not provide new fundamental information to warrant a change in investment thesis. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

BioLife Solutions, BLFS, Form 4, Insider Transaction, Restricted Stock, Executive Compensation, Aby J. Mathew, Share Acquisition, Tax Withholding